Nothing said here yet.
to join the conversation.
The latest fair value estimate for Ovid Therapeutics has shifted from US$5.47 to US$6.02 per share, keeping it within the current analyst price target range of US$5 to US$8. Research firms are linking this move to fresh discussion around OV329.
On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio company with funds advised by Perceptive…
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments.
Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s…